Cheplapharm Arzneimittel GmbH
acquired/legacy branded pharmaceuticals (specialty licensing and commercialization)
Privately held: no public share price · Germany
Assets
(11 total)
11Total Assets
11Approved
0Phase 3 / Filed
0Phase 1–2 / Early
13Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | Glucocorticoid receptor agonistSmall molecule | Asthma | |
| Approved | Fluoropyrimidine (antimetabolite)Small molecule | Breast CancerColorectal CancerGastric CancerPancreatic Cancer HR+/HER2- Metastatic Breast Cancer, Metastatic Colorectal Cancer | |
| Approved | EGFRSmall molecule | Non-Small Cell Lung CancerPancreatic Cancer | |
| Approved | Ribonucleotide reductaseSmall molecule | Sickle Cell Disease | |
| Approved | Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | Schizophrenia | |
| Approved | Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | SchizophreniaBipolar Disorder | |
orlistat(Xenical) | Approved | Pancreatic/gastric lipaseSmall molecule | Obesity |
| Approved | Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | Major Depressive DisorderSchizophreniaBipolar Disorder | |
| Approved | Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | SchizophreniaBipolar Disorder | |
Tretinoin(Vesanoid) | Approved | RARA (retinoic acid receptor alpha); degrades the PML-RARA fusion oncoprotein in APLSmall molecule | Acute Myeloid Leukemia |
Verteporfin(Visudyne) | Approved | Benzoporphyrin-derivative photosensitizer for photodynamic therapySmall molecule | Age-Related Macular Degeneration |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
No financial reports recorded.